medical decision support 1 medical decision support 2
Subscribe Sign In

Nomogram of Han and Partin for Clinically Localized Prostate Cancer

Description

Han and Partin reported a nomogram for evaluating a male with clinically localized prostate cancer. This can help to identify a patient who may be recurrence free following radical prostatectomy. The authors are from the Johns Hopkins University.


Patient selection: male with clinically localized prostate cancer

 

Parameters:

(1) serum PSA in ng/mL

(2) clinical stage from T1a to T3a

(3) Gleason score predominant/primary

(4) Gleason score secondary

 

PSA

Points

.1 to 1

(25.889 * (PSA)) - 2.5889

1 to 6

(0.1975 * ((PSA)^3)) - (2.713 * ((PSA)^2)) + (13.67 * (PSA)) + 12.222

6 to 18

(-0.002615 * ((PSA)^3)) - (0.0974 * ((PSA)^2)) + (6.4696 * (PSA)) + 3.7045

18 to 110

(0.000042 * ((PSA)^3)) - (0.011 * ((PSA)^2)) + (PSA) + 58

 

 

Clinical Stage

Points

T1a or T1b

22.4

T1c

0

T2a

9.1

T2b

30

T2c

23

T3a

47.6

 

 

Primary Gleason

Secondary Gleason

Points

<= 2

<= 2

0

<= 2

3

23

3

<= 2

26.1

3

3

25.8

<= 3

>= 4

46.4

>= 4

NA

48.8

 

total score =

= SUM(points for all of the parameters)

 

Interpretation:

• minimum score: 0

• maximum score: 259

• The higher the score the lower the chances of being recurrence free at 60 months (5 years) after radical prostatectomy.

 

Score

Recurrence Free at 60 Months

< 37.6

> 95%

37.6 to 130

(-0.0000543 * ((score)^2)) + (0.004312* (score)) + 0.8676

130 to 178

(0.00006156 * ((score)^2)) - (0.028562* (score)) + 3.1804

> 178

< 5%

 


To read more or access our algorithms and calculators, please log in or register.

Specialty